OKYO insider trading
NasdaqCM HealthcareOKYO Pharma Ltd: insider trade history from SEC Form 4 filings.
About OKYO Pharma Ltd
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Company website: okyopharma.com
OKYO insider activity at a glance
FilingIQ tracks 23 insider transactions for OKYO in filings since May 18, 2022. The most recent transaction is dated Jul 27, 2026.
Across the full history, 13 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest OKYO Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for OKYO?
- FilingIQ tracks 23 Form 4 insider transactions for OKYO (OKYO Pharma Ltd), covering filings from May 18, 2022 onwards. 2 of those are dated within the last 90 days.
- Are OKYO insiders net buyers or net sellers?
- Across the full Form 4 history for OKYO, 13 transactions (57%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does OKYO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is OKYO in?
- OKYO Pharma Ltd (OKYO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $82.39M.
Methodology & sources
Every OKYO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.